Join the Oncology Voice Network. Join for Free
How Information is Consumed
Medical Science Liaisons Andrew Fariello AstraZeneca data sharing technological advancements

How Information is Consumed


Share This Article


Summary

In this episode, Tom Caravela is joined by Andrew Fariello from AstraZeneca to explore the evolving landscape of Medical Science Liaisons (MSLs) in the context of data sharing and technological advancements. Andrew shares his career journey and insights into the growing importance of surveillance networks and real-world data, especially following the pandemic. The discussion delves into adapting MSL strategies to handle information overload while integrating patient perspectives into medical strategies. Andrew emphasizes the critical role of MSLs, highlighting advancements in engagement and innovative tools. The episode concludes with advice for MSLs navigating scientific developments and a call to action for listeners.

Today’s guest is Andrew Fariello, VP Global Medical Affairs, Head Medical Excellence, Oncology who discusses trends in information/data consumption and what MSLs can do for greater impact

We learn….

πŸ‘‰ How data is being shared as well as how it is being consumed
πŸ‘‰ What he means by the term “instantaneous Information”
πŸ‘‰ What role MSLs play in patient care and patient identification 
πŸ‘‰ How the MSL approach may need to change
πŸ‘‰ Areas of improvement for MSLs in KOL engagement

Click for Source
Medical Science Liaisons, Andrew Fariello, AstraZeneca, data sharing, technological advancements

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN